Literature DB >> 7986970

Clarithromycin-amoxycillin therapy for Helicobacter pylori infection.

M T al-Assi1, R M Genta, T J Karttunen, D Y Graham.   

Abstract

BACKGROUND: More convenient therapies are needed to treat Helicobacter pylori infection successfully. Clarithromycin and amoxycillin are effective against H. pylori both in vivo and in vitro. Recent success with a high dose amoxycillin-metronidazole combination therapy led us to evaluate clarithromycin-amoxycillin dual therapy for H. pylori infection.
METHODS: We tested the combination of clarithromycin 500 mg t.d.s. with meals plus amoxycillin 750 mg t.d.s. with meals for 10 days for its effect on H. pylori infection in 29 patients with documented H. pylori peptic ulcers. There were 27 men and 2 women, ranging in age from 23 to 77 years. H. pylori and ulcer status were evaluated at entry and at least 4 weeks after ending antimicrobial therapy. For ulcer healing, ranitidine 300 mg was given each evening for 6 weeks. H. pylori status was determined by CLOtest and histology.
RESULTS: H. pylori infection was cured in 86% (95% CI = 78-99%). Compliance averaged 93% by pill count. Ten patients (34%) experienced mild side effects: eight reported dysgeusia and two had mild diarrhoea; none discontinued therapy because of side effects.
CONCLUSION: We conclude that dual therapy with clarithromycin and amoxycillin is a safe and effective alternative regimen for the successful treatment of H. pylori infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986970     DOI: 10.1111/j.1365-2036.1994.tb00313.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

Review 1.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

2.  Rescue Therapy for Helicobacter pylori.

Authors:  Wai K. Leung; David Y. Graham
Journal:  Curr Treat Options Gastroenterol       Date:  2002-04

Review 3.  Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship.

Authors:  Akiko Shiotani; Priya Roy; Hong Lu; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2021-12-21       Impact factor: 4.409

4.  Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori.

Authors:  Zi-Han Feng; Ling Fan; Jing Yang; Xing-Yue Huo; Yan Guo; Yi Zhang; Chun-Hui Lan
Journal:  BMC Microbiol       Date:  2019-08-05       Impact factor: 3.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.